Fc Engineered Anti-Human GD2 Therapeutic Antibody, a CDC-Enhanced Biobetter [Lot: CB20-PZ19] (CAT#: BioBet-C019ZP) Datasheet

Target
GD2
Isotype
Whole Chimeric Antibody
Description
CDC-enhanced Dinutuximabis a Fc-modified anti-GD2 therapeutic biobetter. Creative Biolabs' advanced CDC-enhanced antibody platform allows for the production of Fc engineered therapeutic CDC⁺ antibodies. By mutating key amino acids of the Fc region of Dinutuximab, the Fc region of Dinutuximab exhibits a greater binding capacity to C1q, thereby achieving enhanced CDC activity.
Indication
Severe Eosinophilic Asthma
Severe nasal polyposis
Adult patients with eosinophilic granulomatosis
Classification
Therapeutic antibody; biobetter
Patent
Blinatumomab was first received FDA approval in 2014. The patent will expire in the US in 2038.
Status
Preclinical

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Dinutuximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
GD2
Full Name
Disialoganglioside GD2
Alternative Names
dinutuximab;Unituxin;Ch14.18;APN311;Disialoganglioside GD2;Ganglioside G2;GD2
Trade name
Unituxin
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Accession Number
DB09077
CAS number
1363687-32-4
Antibody Isotype
Chimeric IgG1
Description
Dinutuximab is a chimeric monoclonal antibody composed of mouse and human components used as a second-line treatment for children with high-risk neuroblastoma. It targets the glycolipid GD2 expressed on neuroblastoma cells and normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. Dinutuximab obtained marketing authorization in the U.S. and Europe in 2015.
Indication
High Risk Neuroblastoma
Melanoma
Synonyms
Dinutuximab beta
Monoclonal antibody ch14.18
Ch14.18
UNII
7SQY4ZUD30

Dinutuximab is an immunoglobulin G1κ monoclonal antibody that specifically targets the GD2 antigen. GD2 is a transmembrane glycoprotein with many functions and is highly expressed in hematological malignancies, including multiple myeloma tumors. GD2 can regulate receptor-mediated adhesion, signaling, and cyclase and hydrolase activity. Dinutuximab inhibits tumor cell growth and induces broad-spectrum apoptosis by binding to GD2 in a variety of mechanisms: Fc-mediated cross-linking, complement-dependent cytotoxicity, antibody-dependent cytotoxicity, and immune-dependent cell phagocytosis Lead tumor cell lysis.
In vitro experiments show that the effect of dicituzumab-mediated antibody-dependent cytotoxicity (ADCC) with NK cells against neuroblastoma cells has been determined

Dinutuximab is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin 2 (IL-2), and 13-cis-retinoic acid (RA) to treat neuroblastoma in high-risk pediatric patients. Dinutuximab can also be used to treat melanoma

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK